Michael Glenn Miles Net Worth

The estimated Net Worth of Michael Glenn Miles is at least 677 千$ dollars as of 31 January 2019. Michael Miles owns over 150,000 units of Cancer Genetics stock worth over 676,500$ and over the last 6 years Michael sold CGIX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Miles CGIX stock SEC Form 4 insiders trading

Michael has made over 1 trades of the Cancer Genetics stock since 2019, according to the Form 4 filled with the SEC. Most recently Michael bought 150,000 units of CGIX stock worth 34,500$ on 31 January 2019.

The largest trade Michael's ever made was buying 150,000 units of Cancer Genetics stock on 31 January 2019 worth over 34,500$. On average, Michael trades about 75,000 units every 0 days since 2019. As of 31 January 2019 Michael still owns at least 150,000 units of Cancer Genetics stock.

You can see the complete history of Michael Miles stock trades at the bottom of the page.

What's Michael Miles's mailing address?

Michael's mailing address filed with the SEC is 201 ROUTE 17 NORTH, 2ND FLOOR,, C/O CANCER GENETICS INC., RUTHERFORD, NJ, 07070.

Insiders trading at Cancer Genetics

Over the last 12 years, insiders at Cancer Genetics have traded over 1,720,897$ worth of Cancer Genetics stock and bought 3,891,559 units worth 4,573,241$ . The most active insiders traders include John Pappajohn、Tommy G Thompson、John A Roberts. On average, Cancer Genetics executives and independent directors trade stock every 35 days with the average trade being worth of 340,207$. The most recent stock trade was executed by John A Roberts on 31 January 2019, trading 185,436 units of CGIX stock currently worth 42,650$.

What does Cancer Genetics do?

Complete history of Michael Miles stock trades at Cancer Genetics

Cancer Genetics executives and stock owners

Cancer Genetics executives and other stock owners filed with the SEC include:

• Jane Houldsworth,
  Vice President - Research & Development
• Franklyn Prendergast,
  Independent Director
• Howard McLeod,
  Independent Director
• Edmund Cannon,
  Independent Director
• Thomas Widmann,
  Director
• Geoffrey Harris,
  Director
• John Roberts,
  President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer
• John Pappajohn,
  Non-Executive Chairman of the Board
• Panna Sharma,
  Chief Executive Officer
• Raju S.K. Chaganti,
  Director
• Michael J. Welsh,
  Director
• Edward J Sitar,
  Chief Financial Officer
• Igor Gitelman,
  Chief Accounting Officer
• Michael Brian Mc Cartney,
  Chief Commercial Officer
• Michael Glenn Miles,
  Chief Financial Officer
• Ralf Brandt,
  President, Discovery Services
• Rita Shaknovich,
  VP of Hematopathology Services
• Paul Rothman,
  Director
• Keith L Brownlie,
  Director
• Andrew L Pecora,
  Director
• Tommy G Thompson,
  Director
• Steven Hepburn,
  VP of Biopharma Marketing